Pharmacology, Toxicology and Pharmaceutical Science
Muscarinic Receptor
91%
Receptor Subtype
88%
Glucocorticoid
59%
Pirenzepine
55%
Glucocorticoid Receptor
50%
Thrombocyte Activating Factor
36%
Dexamethasone
32%
Thrombocyte Activating Factor Receptor
32%
Binding Site
31%
Leporidae
31%
Methacholine
28%
Transcription Factor AP 1
27%
Disease
24%
Quinuclidinyl Benzilate
22%
Bronchoconstriction
22%
Radioligand
21%
Bronchodilating Agent
21%
Cholinergic Receptor Stimulating Agent
20%
Muscarinic M1 Receptor
19%
Receptor
19%
Cardiovascular Disease
16%
Intubation
16%
Chronic Obstructive Lung Disease
16%
Pertussis Toxin
16%
Guinea Pig
16%
Almitrine Dimesilate
16%
Cholinergic Receptor Blocking Agent
16%
Symptom
16%
Budesonide
16%
Granulocyte Macrophage Colony Stimulating Factor
16%
Emphysema
16%
Bradykinin
16%
Acquired Immune Deficiency Syndrome
16%
Coccidioidomycosis
16%
Infection
16%
Guanine Nucleotide Binding Protein
16%
Muscarinic Receptor Blocking Agent
16%
Asthma
15%
EC50
14%
Phosphatidylinositide
13%
Inflammation
12%
Alternative Complement Pathway C3 C5 Convertase
11%
Nuclear Factor
11%
Carbachol
11%
Antiinflammatory Activity
9%
Autoimmune Disease
8%
Interleukin 1
7%
Edema
7%
Anti-Inflammatory Drug
7%
Scanning Electron Microscopy
6%
Keyphrases
Receptor Subtypes
52%
Peripheral Lung
35%
Muscarinic Receptors
33%
Glucocorticoid Receptor
33%
Muscarinic Cholinergic Receptor
33%
Subclinical Effects
33%
Videolaryngoscopy
33%
Binding Site
31%
Activator protein-1 (AP-1)
25%
Direct Laryngoscopy
25%
Intubation
25%
High Affinity
24%
First Attempt Success
23%
Anti-inflammatory Effect
22%
Coccidioidomycosis
22%
Surgical Intensive Care Unit
21%
Airway Epithelial Cells
20%
Guanine nucleotide
20%
Bronchial Epithelial Cells
20%
Tracheal Smooth muscle
20%
Intensive Care Unit
20%
Esophageal Intubation
20%
Airway
19%
Smokers
19%
Benzil
19%
Respiratory Effects
18%
Platelet-activating Factor
18%
Physiologic
18%
Asthma
18%
Epithelial Cell Line
18%
Platelet-activating Factor Receptor
17%
Primary Bronchial Epithelial Cells
16%
Bronchoscopic
16%
Chronic Obstructive Pulmonary Disease Patient
16%
Autoimmune Disease
16%
Smoke Effect
16%
Non-smokers
16%
Multiple Signaling Pathways
16%
Tobacco Smoke
16%
Neurokinin B
16%
Guinea pig
16%
Pharmacological Characterization
16%
Nuclear factor-B
16%
Chemoprophylaxis
16%
Tuberculosis
16%
Flow-volume Curve
16%
AIDS/HIV
16%
Preventive Treatment
16%
Hypoxemia
16%
Cerebral Cortex
16%
Medicine and Dentistry
Intubation
100%
Intensive Care Unit
81%
Laryngoscopy
67%
Smoking
33%
Coccidioidomycosis
33%
Population
33%
Respiratory Physiology
22%
Odds Ratio
21%
Esophagus Intubation
18%
Difficult Airways
18%
Neuromuscular Blocking Agent
16%
Lung Function
16%
Cytotechnology
16%
Infection
16%
Middle Age
16%
Elastic Recoil
16%
Density Dependence
16%
Acquired Immune Deficiency Syndrome
16%
Chronic Obstructive Pulmonary Disease
16%
Neuromuscular Blocking
16%
Noninvasive Positive Pressure Ventilation
16%
Intensive Care
16%
Symptom
16%
Diffusing Capacity
16%
Transbronchial Biopsy
16%
Bronchoalveolar Lavage Fluid
11%
Human Immunodeficiency Virus Infection
11%
Forced Expiratory Volume
10%
Asthma
10%
Edema
9%
Cigarette Smoking
8%
Logistic Regression Analysis
8%
Tracheal Intubation
6%
Bronchodilating Agent
6%
Observational Study
6%
Diagnosis
5%
Fiber Optics
5%
Expiratory Flow Rate
5%
Lung Mechanics
5%
Lung Volume
5%
Morphology
5%
Human Immunodeficiency Virus
5%
